A Comparative Analysis of Survival and Funding Discrepancies in Cancers With High Mortality
| Autor: | Bradley R. Hall, Pranita Atri, Christopher S. Wichman, Surinder K. Batra, Lynette M. Smith, Andrew Cannon, Chandrakanth Are, Sushil Kumar, Aaron R. Sasson, Hongmei Wang, Apar Kishor Ganti |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Biomedical Research Genital Neoplasms Female 03 medical and health sciences 0302 clinical medicine Prostate Research Support as Topic Internal medicine Epidemiology medicine Carcinoma Humans health care economics and organizations Survival analysis Aged business.industry Prostatic Neoplasms Cancer Middle Aged medicine.disease Survival Analysis National Cancer Institute (U.S.) United States Lymphoma Pancreatic Neoplasms Clinical trial medicine.anatomical_structure 030220 oncology & carcinogenesis Female 030211 gastroenterology & hepatology Surgery business Ovarian cancer Carcinoma Pancreatic Ductal SEER Program |
| Zdroj: | Annals of Surgery. 271:296-302 |
| ISSN: | 1528-1140 0003-4932 |
| Popis: | Objective Comparative analyses of survival and funding statistics in cancers with high mortality were performed to quantify discrepancies and identify areas for intervention. Background Discrepancies in research funding may contribute to stagnant survival rates in pancreatic ductal adenocarcinoma (PDAC). Methods The Surveillance, Epidemiology, and End Results database was queried for survival statistics. Funding data were obtained from the National Cancer Institute (NCI). Clinical trial data were obtained from www.clinicaltrials.gov. Cancers with high mortality were included for analyses. Results Since 1997, PDAC has received lesser funding ($1.41 billion) than other cancers such as breast ($10.52 billion), prostate ($4.93 billion), lung ($4.80 billion), and colorectal ($4.50 billion). Similarly, fewer clinical trials have been completed in PDAC (n = 608) compared with breast (n = 1904), lung (n = 1629), colorectal (n = 1080), and prostate (n = 1055) cancer. Despite this, since 1997, dollars invested in PDAC research produced a greater return on investment with regards to 5-year overall survival (5Y-OS) compared with breast, prostate, uterine, and ovarian cancer. Incremental cost-effectiveness analysis demonstrates that millions (liver, non-Hodgkin lymphoma, and melanoma) and billions (colorectal and lung) of dollars were required for each additional 1% increase in 5Y-OS compared with PDAC. Funding of research towards early diagnosis of PDAC has decreased by 19% since 2007. For nearly all cancers, treatment-related research receives the highest percentage of NCI funding. Conclusions Funding of PDAC research is significantly less than other cancers, despite its higher mortality and greater potential to improve 5Y-OS. Increased awareness and lobbying are required to increase funding, promote research, and improve survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|